Researchers from the University of British Columbia and Vancouver Coastal Health Research Institute have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients.

The study, published today in the journal Brain, found that people with MS who took a beta interferon drug had a 32 per cent lower mortality risk than those that did not take the drug. This was particularly evident among MS patients who took beta interferon for more than three years.


https://www.sciencedaily.com/releases/2019/03/190318132638.htm